a Department of Internal Medicine, Oshima Clinic , Saitama , Japan.
b Department of Nephrology , Saitama Medical School , Saitama , Japan.
Ren Fail. 2018 Nov;40(1):38-42. doi: 10.1080/0886022X.2017.1419971.
This study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). A total of 23 HD patients under the treatment with cinacalcet and 101 control patients were enrolled in this cross-sectional study. We investigated the prevalence of gallstones and the association of GI adverse events of cinacalcet with gallstones. The prevalence of gallstones was significantly higher in the HD patients with cinacalcet compared with the controls (47.8% vs. 15.8%). The longer time on HD, hypercalcemia, hyperphosphatemia and elevated parathyroid hormone level were observed in the HD patients with cinacalcet. Besides, GI adverse events of cinacalcet were observed more frequently in the HD patients with gallstones compared with those without gallstones (odds ratio 13.5, 95% CI: 1.80-101). Therefore, screening for gallstones before dosing cinacalcet may reduce the risk of GI adverse events in SHPT patients.
本研究旨在探讨西那卡塞治疗继发性甲状旁腺功能亢进（SHPT）的血液透析（HD）患者胃肠道（GI）不良事件与胆结石之间的关系。本横断面研究共纳入 23 名接受西那卡塞治疗的 HD 患者和 101 名对照患者。我们调查了胆结石的患病率，并探讨了西那卡塞的 GI 不良事件与胆结石之间的关系。与对照组相比，接受西那卡塞治疗的 HD 患者胆结石的患病率显著更高（47.8% vs. 15.8%）。接受西那卡塞治疗的 HD 患者中，HD 时间更长、血钙升高、血磷升高和甲状旁腺激素水平升高。此外，与无胆结石的患者相比，有胆结石的患者更常出现西那卡塞的 GI 不良事件（比值比 13.5，95%CI：1.80-101）。因此，在开始使用西那卡塞之前筛查胆结石可能会降低 SHPT 患者发生 GI 不良事件的风险。
